REVIEW article
Front. Genet.
Sec. Genetics of Common and Rare Diseases
Volume 16 - 2025 | doi: 10.3389/fgene.2025.1599088
This article is part of the Research TopicFertilization and Early Development: Genetics and Epigenetics, Volume IIView all 3 articles
The clinical application and challenges of preimplantation genetic testing
Provisionally accepted
- West China Second University Hospital, Sichuan University, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Preimplantation genetic testing (PGT) has rapidly advanced due to the significant development of genetic testing technologies. As an integration of genetic testing and assisted reproductive technology (ART), PGT plays a pivotal role in the primary prevention of birth defects, mainly chromosomal abnormalities and monogenic disease with known pathogenic variants. Blastocyst biopsy entails the collection of a relatively higher number of cells compared to other methods. Thereafter, whole genome amplification (WGA) generates a substantially larger amount of DNA templates, enabling more accurate subsequent genetic analyses. As an evolving technique that continues to be improved, the inherent limitations of WGA are expected to be minimized in the near future. Despite the widespread application of genetic techniques to WGA products, challenges remain in the downstream detection of small-fragment copy number variations (CNVs) (particularly those 1Mb), the inability of long-read sequencing to resolve haplotypes or determine the position and orientation of micro-duplications for specific genomic sequences. Additionally, identifying complex or cryptic structures of balanced chromosomal rearrangements in prospective parents with a history of adverse pregnancy outcomes represents an urgent and challenging task, which would facilitate the pre-testing evaluation of PGT indications. Meanwhile, further assessment of the risks associated with transferring embryos with mosaic chromosome abnormalities, the implantation potential of euploid embryos, as well as the long-term health outcomes of children born following PGT requires more rigorously designed studies to provide robust evidence. The technology of PGT will continue to evolve, becoming increasingly comprehensive and precise. However, this technology should be applied strictly in accordance with legislation and ethical guidelines, with the ultimate aim of benefiting couples.
Keywords: preimplantation genetic testing, chromosomal structural rearrangement, Monogenic disease, Aneuploidies, clinical application, Challenges
Received: 24 Mar 2025; Accepted: 22 May 2025.
Copyright: © 2025 Zhou, Chen, Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fan Zhou, West China Second University Hospital, Sichuan University, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.